

Haematologica
HAEMATOL/2017/183525
Version 3

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

Yann Ferret, Nicolas Boissel, Nathalie Helevaut, Jordan Madic, Olivier Nibourel, Alice Marceau-Renaut, Maxime Bucci, Sandrine Geffroy, Karine Celli-Lebras, Sylvie Castaigne, Xavier Thomas, Christine Terré, Hervé Dombret, Claude Preudhomme, and Aline Renneville

Disclosures: This work was supported by the Association Laurette Fugain, the Ligue Contre le Cancer (North Center), the SIRIC ONCOLille, the North-West Canceropole (GIRCI AAP-AE 2015_53), and the Institut National du Cancer - Direction Generale de l'Offre de Soins (INCA-DGOS_9967). The authors declare no conflicts of interest.

Contributions: YF, NH, JM, ON, AMR, MB, SG, KCL, CT performed research or collected data; YF, NB, and AR performed data analysis and wrote the paper; SC and XT were the principal investigators of the ALFA-0701 and ALFA-0702 trials, respectively; HD is the president of the ALFA group; CP and AR supervised the study.